What the FDA Relabeling of Abacavir Means for You and Your Patient
Abacavir
November 2008
Abacavir is a nucleoside reverse transcriptase inhibiting of the human immunodeficiency virus. It is used in HAART therapy in combination with other anti-HIV drugs. It is marketed in the United States as Ziagen as a single drug, or as a fixed combination with other drugs and marketed as Epzicon and Trizivir.
Abacavir |
Jump to section:
- Introduction
- Highly Active Antiretroviral Therapy
- Abacavir
- FDA Caution and Relabeling
- Abacavir Hypersensitivity
- Abacavir HSR and HLA Gene
- HLA-B Antigens and Alleles
- Naming Conventions - HLA-B*5701
- Chromosome 6
- Detecting HLA Alleles
- HLA-B*5701 Correlations
- HLA-B*5701 Correlations
- Clinical Utility3
- Problems
- If HSR Symptoms are Present4
- If HSR Symptoms are Present4
- Recommendations for Physicians5
- Recommendations for Physicians5
- Information for Patients5
- Information for Patients5
- HLA-B*5701 Genotyping
- References
- Questions?
External
link
PDF
document
Excel
document
Word
document